Hims & Hers health CEO sells over $747k in company stock

Andrew Dudum, CEO of Hims & Hers Health, Inc. (NYSE:HIMS), has sold a total of $747,433 worth of company stock, according to a recent filing with the Securities and Exchange Commission. The transactions, which took place on September 20, 2024, involved sales of shares at prices ranging from $16.2922 to $16.7798.

Specifically, Dudum offloaded 42,099 shares at an average price of $16.2922 and an additional 3,668 shares at an average price of $16.7798. The sales were conducted under a prearranged Rule 10b5-1 trading plan, which allows company insiders to sell stock at predetermined times to avoid accusations of insider trading.

Following these transactions, the CEO still holds a significant number of shares in Hims & Hers Health, directly and indirectly through trusts. The direct holdings that were affected by the recent sale now stand at 67,015 shares.

Investors often keep a close eye on insider sales as they may provide insights into an executive's perspective on the company's current valuation and future prospects. However, it's also not uncommon for executives to sell shares for personal financial management reasons, including diversification and liquidity.

Hims & Hers Health, Inc. continues to be a notable player in the healthcare industry, providing accessible and convenient digital health services. The company's stock performance and insider transactions are of particular interest to investors tracking the health sector's growth and the movements of its executives.



In other recent news, Hims & Hers Health, a health and wellness platform, has announced several significant developments. The company reported a 52% year-over-year revenue increase in Q2 2024, reaching $316 million, along with an adjusted EBITDA of $39 million. Additionally, the company issued 976,341 Class A common shares to Nivagen Pharmaceuticals as part of the acquisition of MedisourceRx, expanding its product offerings and market reach.

In terms of analyst reviews, Citi maintained a Neutral rating, while Needham initiated a Buy rating. Conversely, Jefferies reduced its price target, citing a need to update their financial model. Deutsche Bank increased its target, emphasizing the company's growth prospects.

Hims & Hers Health also launched a Service Appreciation Initiative aimed at providing discounted weight loss treatments to U.S. military, veterans, teachers, nurses, and first responders. The company's entry into the compounded GLP-1 space has been a point of interest among analysts. For 2024, the company projects its revenue to fall between $1.37 billion and $1.4 billion, with an adjusted EBITDA between $140 million and $155 million.
InvestingPro Insights


In light of the recent insider sales by CEO Andrew Dudum, it's worth noting a few key metrics and insights from InvestingPro that could provide additional context for investors considering Hims & Hers Health, Inc. (NYSE:HIMS). According to InvestingPro, the company boasts a solid revenue growth, with the last twelve months as of Q2 2024 showing a significant increase of over 50%. This impressive growth rate indicates a strong market demand for the company's digital health services.

InvestingPro Tips highlight that management has been actively engaged in share buybacks, which often reflects confidence in the company's future performance. Additionally, Hims & Hers Health is expected to see net income growth this year, which may reassure investors looking for profitability in their investments. Furthermore, with three analysts revising their earnings upwards for the upcoming period, there is an optimistic outlook on the company's financial prospects.

From a valuation standpoint, Hims & Hers Health is currently trading at a high earnings multiple, with a P/E ratio of 193.29. This valuation suggests that investors are willing to pay a premium for the company's shares, possibly due to the anticipated growth and profitability. However, it's important to consider that the company is also trading at a high P/E ratio relative to near-term earnings growth, indicating that the stock may be priced optimistically.

For those interested in further insights, InvestingPro offers additional tips on Hims & Hers Health, Inc., which can be found at https://www.investing.com/pro/HIMS. These tips provide further analysis and data points that could be crucial for making informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com